Patrick G.  LePore net worth and biography

Patrick LePore Biography and Net Worth

Director of VYNE Therapeutics
Patrick G. LePore is a businessperson who has been at the head of 6 different companies and currently holds the position of Independent Non-Executive Chairman at Lannett Co., Inc., Chairman at Lautus Pharmaceuticals LLC and Chairman at Endo Generics Holdings, Inc. He is also on the board of Matinas BioPharma Holdings, Inc., Villanova University, Tyme, Inc. and VYNE Therapeutics, Inc.

In his past career Patrick G. LePore occupied the position of Chairman for AgeneBio, Inc., President-Healthcare Marketing Group at Cardinal Health, Inc. and Chairman, President & Chief Executive Officer at Boron, LePore & Associates, Inc. (a subsidiary of Cardinal Health, Inc.) and Chairman, President & Chief Executive Officer of Par Pharmaceutical, Inc.

Patrick G. LePore received an undergraduate degree from Villanova University and an MBA from Fairleigh Dickinson University.

What is Patrick G. LePore's net worth?

The estimated net worth of Patrick G. LePore is at least $111,239.60 as of November 15th, 2023. Mr. LePore owns 36,472 shares of VYNE Therapeutics stock worth more than $111,240 as of March 28th. This net worth evaluation does not reflect any other investments that Mr. LePore may own. Learn More about Patrick G. LePore's net worth.

How do I contact Patrick G. LePore?

The corporate mailing address for Mr. LePore and other VYNE Therapeutics executives is 520 U.S. HIGHWAY 22 SUITE 204, BRIDGEWATER NJ, 08807. VYNE Therapeutics can also be reached via phone at (800) 755-7936 and via email at [email protected]. Learn More on Patrick G. LePore's contact information.

Has Patrick G. LePore been buying or selling shares of VYNE Therapeutics?

Patrick G. LePore has not been actively trading shares of VYNE Therapeutics within the last three months. Most recently, on Wednesday, November 15th, Patrick G. Lepore bought 13,000 shares of VYNE Therapeutics stock. The stock was acquired at an average cost of $3.91 per share, with a total value of $50,830.00. Following the completion of the transaction, the director now directly owns 36,472 shares of the company's stock, valued at $142,605.52. Learn More on Patrick G. LePore's trading history.

Are insiders buying or selling shares of VYNE Therapeutics?

During the last year, VYNE Therapeutics insiders bought shares 1 times. They purchased a total of 13,000 shares worth more than $50,830.00. The most recent insider tranaction occured on November, 15th when Director Patrick G Lepore bought 13,000 shares worth more than $50,830.00. Insiders at VYNE Therapeutics own 1.8% of the company. Learn More about insider trades at VYNE Therapeutics.

Information on this page was last updated on 11/15/2023.

Patrick G. LePore Insider Trading History at VYNE Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/15/2023Buy13,000$3.91$50,830.0036,472View SEC Filing Icon  
3/20/2023Buy20,000$2.48$49,600.0023,472View SEC Filing Icon  
11/30/2021Buy694$18.36$12,741.84View SEC Filing Icon  
8/25/2021Buy694$28.80$19,987.20View SEC Filing Icon  
5/26/2021Buy694$64.80$44,971.202,083View SEC Filing Icon  
12/3/2020Buy2,777$30.78$85,476.062,777View SEC Filing Icon  
See Full Table

Patrick G. LePore Buying and Selling Activity at VYNE Therapeutics

This chart shows Patrick G Lepore's buying and selling at VYNE Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

VYNE Therapeutics Company Overview

VYNE Therapeutics logo
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan-BET inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal inhibitor for the treatment of immuno-inflammatory indications; and FMX114, a combination gel formation of tofacitinib and fingolimod, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.
Read More

Today's Range

Now: $3.05
Low: $2.98
High: $3.05

50 Day Range

MA: $2.13
Low: $1.71
High: $2.96

2 Week Range

Now: $3.05
Low: $1.67
High: $8.73

Volume

24,537 shs

Average Volume

124,204 shs

Market Capitalization

$43.01 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.18